25.41
前日終値:
$25.54
開ける:
$24.95
24時間の取引高:
10.07M
Relative Volume:
0.90
時価総額:
$29.14B
収益:
$16.70B
当期純損益:
$-157.13M
株価収益率:
-175.73
EPS:
-0.1446
ネットキャッシュフロー:
$1.19B
1週間 パフォーマンス:
+6.01%
1か月 パフォーマンス:
+26.36%
6か月 パフォーマンス:
+50.44%
1年 パフォーマンス:
+51.70%
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
名前
Teva Pharmaceutical Industries Ltd Adr
セクター
電話
972 (3) 914-8213
住所
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
TEVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-05-28 | 開始されました | Truist | Buy |
| 2025-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-07-10 | アップグレード | Argus | Hold → Buy |
| 2024-03-08 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-02-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | アップグレード | Jefferies | Hold → Buy |
| 2024-01-03 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-11-27 | アップグレード | UBS | Neutral → Buy |
| 2023-07-06 | アップグレード | UBS | Sell → Neutral |
| 2023-05-25 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-05-18 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-01-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-11-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | UBS | Neutral → Sell |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-08-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-06-14 | 再開されました | UBS | Neutral |
| 2022-05-17 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-05-04 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-03-25 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | ダウングレード | Argus | Buy → Hold |
| 2021-10-28 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | ダウングレード | UBS | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 開始されました | Oppenheimer | Perform |
| 2020-08-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 再開されました | Goldman | Neutral |
| 2020-06-01 | アップグレード | SunTrust | Hold → Buy |
| 2020-04-24 | 再開されました | Citigroup | Neutral |
| 2020-04-06 | アップグレード | UBS | Neutral → Buy |
| 2020-02-24 | ダウングレード | Edward Jones | Hold → Sell |
| 2019-11-12 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-10-17 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-08-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 開始されました | Wolfe Research | Peer Perform |
| 2019-07-15 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 再開されました | Credit Suisse | Neutral |
| 2019-07-05 | アップグレード | Argus | Hold → Buy |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-06-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | ダウングレード | UBS | Buy → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2019-03-07 | 再開されました | UBS | Buy |
すべてを表示
Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz
Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at $25.96 - Investing.com
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? - sharewise.com
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living - GlobeNewswire Inc.
Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margins - Morningstar
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Sahm
Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges - Investing.com
Teva stock hits 52-week high at 23.07 USD - Investing.com
Teva stock hits 52-week high at 23.07 USD By Investing.com - Investing.com Philippines
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm
Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Price and Chart — VIE:TEVA - TradingView
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - Sahm
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 - Finviz
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm
SciSparc And AutoMax Call Off Merger - Sahm
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm
Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se
TEVA Stock Price and Chart — TASE:TEVA - TradingView
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com
Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com
Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva
TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva
Teva Pharmaceutical Industries Ltd Adr (TEVA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):